BH3 谱析揭示芦可替尼可作为维奈克拉治疗 T-PLL 的潜在联合药物
JAK1/2 抑制剂芦可替尼或 HDAC 抑制剂贝利司他均可增加对 BCL-2 的依赖,使 T-PLL 细胞对维奈克拉敏感。据此联合治疗 2 例难治性 T-PLL,JAK3 突变者获深度缓解,非突变者疾病稳定。
要点
- 原发 T-PLL 细胞主要依赖 BCL-2 和 MCL-1 抗凋亡蛋白存活
- 芦可替尼或贝利司他增加 BCL-2 依赖,使 T-PLL 对维奈克拉敏感
- 维奈克拉联合芦可替尼在 2 例难治性 T-PLL 中显示初步疗效
核心结论
- BH3 谱析提示 T-PLL 主要依赖 BCL-2 与 MCL-1,抑制 JAK/STAT 或 HDAC 可增强对 BCL-2 的依赖并增敏维奈克拉。
- 维奈克拉联合芦可替尼在难治性 T-PLL 中显示初步临床活性,值得进一步临床探索。
研究设计与样本
- 基于体外结果,对 2 例难治性 T-PLL 患者给予维奈克拉联合芦可替尼治疗。
主要发现
- 原发 T-PLL 细胞凋亡启动水平相对较低,主要依赖 BCL-2 和 MCL-1 蛋白存活。
- 选择性药物抑制 BCL-2 或 MCL-1 均可诱导原发 T-PLL 细胞死亡。
- 芦可替尼或贝利司他分别增加 T-PLL 细胞对 BCL-2 而非 MCL-1 的依赖,从而增敏维奈克拉。
- 2 例难治性 T-PLL 中,JAK3 突变者获深度缓解,非突变者疾病稳定。
临床怎么用
- 对难治性 T-PLL 可考虑维奈克拉联合芦可替尼,尤其 JAK3 突变者可能获益更深。
- BH3 谱析可作为功能精准医学工具,指导 T-PLL 的凋亡依赖靶向联合方案选择。
局限性
- 联合治疗的临床证据仅来自 2 例难治性 T-PLL 患者,样本量有限。
- BH3 谱析为体外功能检测,其结果向临床应用的转化仍需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity. Several novel agent classes have demonstrated preclinical activity in T-PLL, including inhibitors of the JAK/STAT and T-cell receptor pathways, as well as histone deacetylase (HDAC) inhibitors. Recently, the BCL-2 inhibitor venetoclax also showed some clinical activity in T-PLL. We sought to characterize functional apoptotic dependencies in T-PLL to identify a novel combination therapy in this disease. Twenty-four samples from patients with primary T-PLL were studied by using BH3 profiling, a functional assay to assess the propensity of a cell to undergo apoptosis (priming) and the relative dependence of a cell on different antiapoptotic proteins. Primary T-PLL cells had a relatively low level of priming for apoptosis and predominantly depended on BCL-2 and MCL-1 proteins for survival. Selective pharmacologic inhibition of BCL-2 or MCL-1 induced cell death in primary T-PLL cells. Targeting the JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax. Based on these results, we treated 2 patients with refractory T-PLL with a combination of venetoclax and ruxolitinib. We observed a deep response in JAK3-mutated T-PLL and a stabilization of the nonmutated disease. Our functional, precision-medicine-based approach identified inhibitors of HDAC and the JAK/STAT pathway as promising combination partners for venetoclax, warranting a clinical exploration of such combinations in T-PLL.
引用
- Herbaux C, Kornauth C, Poulain S, et al. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021. PMID: 33598678. doi:10.1182/blood.2020007303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。